Skip to main content
Faraz Bishehsari, MD, Gastroenterology, Houston, TX

Faraz Bishehsari MD

Advanced Endoscopic Interventional


Physician

Join to view full profile
  • 6431 Fannin St# 4.234Houston, TX 77030

  • Phone+1 713-500-6683

  • Fax+1 713-500-6699

Dr. Bishehsari is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Tehran University of Medical Sciences School of Medicine
    Tehran University of Medical Sciences School of MedicineClass of 2005

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2011 - 2029
  • TX State Medical License
    TX State Medical License 2024 - 2027
  • PA State Medical License
    PA State Medical License 2008 - 2011
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Gastroenterology
    American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2015-2017

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Pancreatic Cancer Researcher Earns NIH Honor
    Pancreatic Cancer Researcher Earns NIH HonorOctober 4th, 2022
  • Opioid Use Identified as Potential Pancreatic Cancer Risk Factor
    Opioid Use Identified as Potential Pancreatic Cancer Risk FactorFebruary 16th, 2021
  • 08 Jan Could Opioids Account for the Rise of Pancreatic Cancer?
    08 Jan Could Opioids Account for the Rise of Pancreatic Cancer?January 8th, 2021

Grant Support

  • Fibrin-laden tumor stroma as a novel immunomodulatory factor in pancreatic ductal adenocarcinomaUTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH2026–2031
  • Microbial-based platform for assessing organ damage in alcohol use disorders (AUD)UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2025–2030
  • Impact of Circadian-Microbiome Interaction on the Gut-Pancreas Axis in AgingUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2024–2029
  • Development of a precision medicine platform for circadian based therapeutics in pancreatic cancerUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2024–2027
  • Discovery of Chronotherapeutic Candidate Targets in Pancreatic CancerUNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON2025–2026

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: